Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
NeoGenomics (NEO)
NASDAQ:NEO
Holding NEO?
Track your performance easily
NEO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$12.77 - $21.22
Previous Close$13.59
Volume700.20K
Average Volume (3M)687.44K
Market Cap
$1.74B
Enterprise Value$1.96B
Total Cash (Recent Filing)$387.86M
Total Debt (Recent Filing)$606.52M
Price to Earnings (P/E)―
Beta1.90
Next Earnings
Nov 05, 2024EPS Estimate
$0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.62
Shares Outstanding128,158,151
10 Day Avg. Volume573,374
30 Day Avg. Volume687,437
Standard Deviation0.17
R-Squared0.13
Alpha-0.00497
Financial Highlights & Ratios
Price to Book (P/B)1.90
Price to Sales (P/S)2.75
Price to Cash Flow (P/CF)31.10
P/FCF Ratio531.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.12
Enterprise Value/Gross Profit8.01
Enterprise Value/Ebitda399.17
Forecast
1Y Price Target
$21.25Price Target Upside56.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
NeoGenomics News
PremiumCompany Announcements
NeoGenomics Reports Strong Q3 2024 Growth
PremiumCompany Announcements
NeoGenomics Reports Strong Q3 2024 Revenue Growth
PremiumPre-Earnings
Is NEO a Buy, Before Earnings?
Bulls Say, Bears Say
Bulls Say
Financial PerformanceNEO delivered 2Q24 revenue of $165M, beating expectations, with the beat primarily driven by AUP upside from clinical testing from NGS growth and revenue cycle management.
Market PositionNEO is seen as a one-stop oncology lab testing service provider, with growth opportunities in NGS products, biopharma Dx services and a profitable long-term outlook as a cancer Dx testing company.
Product And InnovationNEO intends to launch a NEO Comprehensive Liquid (PanTracer LBx) assay followed by a solid tumor WGS panel.
Bears Say
Legal IssuesRaDaR receives permanent injunction.
Market CompetitionFurther delays on MRD would not be ideal for NEO, with GH's revamped Reveal assay already on the market.
Patent LitigationNatera disclosed that it had won a permanent injunction during its patent infringement lawsuit against NEO's RaDaR 1.0 liquid biopsy test.
---
Ownership Overview
1.16% Insiders
36.49% Mutual Funds
2.85% Other Institutional Investors
34.25% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NEO FAQ
What was NeoGenomics’s price range in the past 12 months?
NeoGenomics lowest stock price was $12.77 and its highest was $21.22 in the past 12 months.
What is NeoGenomics’s market cap?
Currently, no data Available
When is NeoGenomics’s upcoming earnings report date?
NeoGenomics’s upcoming earnings report date is Nov 05, 2024 which is yesterday.
How were NeoGenomics’s earnings last quarter?
NeoGenomics released its earnings results on Jul 29, 2024. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of -$0.003 by $0.033.
Is NeoGenomics overvalued?
According to Wall Street analysts NeoGenomics’s price is currently Undervalued.
Does NeoGenomics pay dividends?
NeoGenomics does not currently pay dividends.
What is NeoGenomics’s EPS estimate?
NeoGenomics’s EPS estimate is $0.01.
How many shares outstanding does NeoGenomics have?
NeoGenomics has 128,158,160 shares outstanding.
What happened to NeoGenomics’s price movement after its last earnings report?
NeoGenomics reported an EPS of $0.03 in its last earnings report, beating expectations of -$0.003. Following the earnings report the stock price went up 17.964%.
Which hedge fund is a major shareholder of NeoGenomics?
Among the largest hedge funds holding NeoGenomics’s share is Royce & Associates LLC. It holds NeoGenomics’s shares valued at 9M.
---
NeoGenomics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.25 (56.36% Upside)
$21.25 (56.36% Upside)
Hedge Fund Trend
Increased
By 76.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 1.4%
Last 30 Days ▼ 1.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-3.06%
12-Months-Change
Fundamentals
Return on Equity
-8.39%
Trailing 12-Months
Asset Growth
-3.06%
Trailing 12-Months
Company Description
NeoGenomics
NeoGenomics, Inc. is a clinical laboratory, which specializes in cancer genetics diagnostic testing and pharma services. It operates through the following two segments: Clinical and Pharma Services. The Clinical Services segment offers clinical cancer testing services to community-based pathologists. The Pharma Services segments supports pharmaceutical firms in their drug development programs by supporting various clinical trials and research. The Clinical Services Segment provides various clinical testing services to community-based pathology practices, hospital pathology labs and academic centers with reimbursement from various payers including client direct billing, commercial insurance, Medicare and other government payers, and patients. The Pharma Services segment: provides comprehensive testing services in supports pharmaceutical clients' oncology programs from discovery to commercialization. Its services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, immunohistochemistry, anatomic pathology and molecular genetic testing. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.
---
NEO Company Deck
---
NEO Earnings Call
Q2 2024
0:00 / 0:00
---
NEO Stock 12 Month Forecast
Average Price Target
$21.25
▲(56.36% Upside)
Technical Analysis
Best Analysts Covering NEO
1 Year
1 Year Success Rate
7/15 ratings generated profit
1 Year Average Return
-1.07%
reiterated a buy rating last month
Copying Bruce Jackson's trades and holding each position for 1 Year would result in 46.67% of your transactions generating a profit, with an average return of -1.07% per trade.
---